表紙
市場調査レポート

GP Pharm, S.A. - 製品パイプライン分析

GP Pharm, S.A. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251670
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
GP Pharm, S.A. - 製品パイプライン分析 GP Pharm, S.A. - Product Pipeline Review - 2015
出版日: 2015年07月31日 ページ情報: 英文 32 Pages
概要

GP Pharm, S.A.は、泌尿器系および腫瘍の治療で用いる注射製剤の研究・開発と製造、販売を行っている製薬会社です。また、受託生産も行っています。

当レポートでは、GP Pharm, S.A.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

GP Pharm, S.A.の基本情報

GP Pharm, S.A.の概要

  • 主要情報
  • 企業情報

GP Pharm, S.A.:R&Dの概要

  • 主な治療範囲

GP Pharm, S.A.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

GP Pharm, S.A.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

GP Pharm, S.A.▼初期段階にあるパイプライン製品

前臨床段階にある製品/併用療法モダリティ

GP Pharm, S.A.:薬剤プロファイル

  • desmopressin acetate
  • leuprolide acetate
  • leuprolide acetate depot 3 months
  • doxorubicin liposomal
  • octreotide acetate LAR
  • octreotide acetate MAR
  • triptorelin depot 1 month
  • triptorelin depot 3 months
  • docetaxel liposomal third generation
  • doxorubicin liposomal third generation
  • gemcitabine liposomal third generation
  • goserelin 3 months depot
  • GP-1100
  • GP-1200
  • irinotecan hydrochloride liposomal third generation
  • leuprolide acetate depot 6 months
  • Pegylated liposomal doxorubicin
  • risperidone depot

GP Pharm, S.A.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

GP Pharm, S.A.:最近のパイプライン動向

GP Pharm, S.A.:休止中のプロジェクト

GP Pharm, S.A.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07264CDB

Summary

Global Markets Direct's, 'GP Pharm, S.A. - Product Pipeline Review - 2015', provides an overview of the GP Pharm, S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GP Pharm, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of GP Pharm, S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of GP Pharm, S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the GP Pharm, S.A.'s pipeline products

Reasons to buy

  • Evaluate GP Pharm, S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of GP Pharm, S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the GP Pharm, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of GP Pharm, S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of GP Pharm, S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of GP Pharm, S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • GP Pharm, S.A. Snapshot
    • GP Pharm, S.A. Overview
    • Key Information
    • Key Facts
  • GP Pharm, S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • GP Pharm, S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • GP Pharm, S.A. - Pipeline Products Glance
    • GP Pharm, S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • GP Pharm, S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • GP Pharm, S.A. - Drug Profiles
    • octreotide acetate LAR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • octreotide acetate MAR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triptorelin depot 1 month
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triptorelin depot 3 months
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel liposomal third generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • doxorubicin liposomal third generation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gemcitabine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • goserelin 3 months depot
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Irinotecan Hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate depot 6 months
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Doxorubicin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • risperidone depot
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • GP Pharm, S.A. - Pipeline Analysis
  • GP Pharm, S.A. - Pipeline Products by Target
  • GP Pharm, S.A. - Pipeline Products by Route of Administration
  • GP Pharm, S.A. - Pipeline Products by Molecule Type
  • GP Pharm, S.A. - Pipeline Products by Mechanism of Action
  • GP Pharm, S.A. - Dormant Projects
  • GP Pharm, S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • GP Pharm, S.A., Key Information
  • GP Pharm, S.A., Key Facts
  • GP Pharm, S.A. - Pipeline by Indication, 2015
  • GP Pharm, S.A. - Pipeline by Stage of Development, 2015
  • GP Pharm, S.A. - Monotherapy Products in Pipeline, 2015
  • GP Pharm, S.A. - Phase II, 2015
  • GP Pharm, S.A. - Phase I, 2015
  • GP Pharm, S.A. - Preclinical, 2015
  • GP Pharm, S.A. - Pipeline by Target, 2015
  • GP Pharm, S.A. - Pipeline by Route of Administration, 2015
  • GP Pharm, S.A. - Pipeline by Molecule Type, 2015
  • GP Pharm, S.A. - Pipeline Products by Mechanism of Action, 2015
  • GP Pharm, S.A. - Dormant Developmental Projects,2015
  • GP Pharm, S.A., Other Locations

List of Figures

  • GP Pharm, S.A. - Pipeline by Top 10 Indication, 2015
  • GP Pharm, S.A. - Pipeline by Stage of Development, 2015
  • GP Pharm, S.A. - Monotherapy Products in Pipeline, 2015
  • GP Pharm, S.A. - Pipeline by Top 10 Target, 2015
  • GP Pharm, S.A. - Pipeline by Top 10 Route of Administration, 2015
  • GP Pharm, S.A. - Pipeline by Top 10 Molecule Type, 2015
  • GP Pharm, S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top